Pharmacokinetics and pharmacodynamics of intravenous versus enteral amiodarone in critically ill patients with new-onset atrial fibrillation – a randomised controlled pilot trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521289-88-02

Acronym

2025-521289-88-00

Enrollment

Registered

2025-06-06

Start date

2025-09-01

Completion date

Unknown

Last updated

2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

New-onset atrial fibrillation

Brief summary

Pharmacokinetic of amiodarone

Detailed description

Pharmacodynamics of amiodarone

Interventions

DRUGAmiodarone Hydrochloride 50 mg/ml Concentrate for Solution for Injection/Infusion

DRUGCordan

DRUGtabletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic of amiodarone	—

Secondary

Measure	Time frame
Pharmacodynamics of amiodarone	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026